By Michael Susin

AstraZeneca said that its drug Enhertu, which it developed in partnership with Daiichi Sankyo, has been approved in the European Union for the treatment of advanced non-small cell lung cancer.

The Anglo-Swedish pharma giant on Monday said that it will receive $75 million from Daiichi as a milestone payment.

AstraZeneca added that the approval comes after positive clinical trial data.

The company added that sales of Enhertu in most of the E.U. territories are recognised by its partner.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

October 23, 2023 02:34 ET (06:34 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
過去 株価チャート
から 5 2024 まで 6 2024 Daiichi Sankyo (PK)のチャートをもっと見るにはこちらをクリック
Daiichi Sankyo (PK) (USOTC:DSNKY)
過去 株価チャート
から 6 2023 まで 6 2024 Daiichi Sankyo (PK)のチャートをもっと見るにはこちらをクリック